Search

Displaying results 3321 - 3330 of 10000 in total
  1. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    It is amphoteric in nature, and is used in various chemical, industrial and commercial applications. It is considered an indirect additive used in food contact substances by the FDA.

    Mixtures: POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOS
  2. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

    Categories: Penicillin G
  3. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)

  4. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.

  5. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

  6. Drug

    CER-001

    go.drugbank.com/drugs/DB18538
    Investigational

    [L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies. … CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol.

  7. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents.

  8. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  9. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    are placed at higher risk for developing life-threatening or fatal infections and immune dysregulation. … [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three.

  10. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    approved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was